
BioNano Genomics BNGO
$ 1.18
-0.01%
Annual report 2025
added 03-23-2026
BioNano Genomics Cash Conversion Cycle 2011-2026 | BNGO
Annual Cash Conversion Cycle BioNano Genomics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 166 | 225 | 319 | 236 | 104 | 144 | 268 | 125 | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 319 | 104 | 198 |
Quarterly Cash Conversion Cycle BioNano Genomics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124 | 171 | 202 | - | 156 | 335 | 331 | - | 348 | 348 | 380 | - | 169 | 123 | 200 | - | 87 | 94.4 | 94.7 | - | 139 | 273 | 426 | 247 | 203 | 309 | 285 | 94 | 137 | 107 | 155 | 70.3 | 39.3 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 426 | 39.3 | 202 |
Cash Conversion Cycle of other stocks in the Diagnostics research industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
50.2 | - | -6.23 % | $ 30.6 M | ||
|
Biodesix
BDSX
|
41.7 | $ 15.87 | 2.09 % | $ 2.06 B | ||
|
Biomerica
BMRA
|
172 | $ 2.06 | -4.73 % | $ 4.73 M | ||
|
Bioventus
BVS
|
224 | $ 9.25 | 1.09 % | $ 616 M | ||
|
Mettler-Toledo International
MTD
|
66.4 | $ 1 276.51 | 0.86 % | $ 26.3 B | ||
|
Akumin
AKU
|
36.1 | - | -17.87 % | $ 25.9 M | ||
|
Myriad Genetics
MYGN
|
49.3 | $ 4.79 | 3.9 % | $ 444 M | ||
|
Guardant Health
GH
|
79.6 | $ 86.3 | 3.24 % | $ 10.8 B | ||
|
Enzo Biochem
ENZ
|
154 | - | -8.98 % | $ 14.8 K | ||
|
Natera
NTRA
|
81.5 | $ 202.01 | 3.85 % | $ 19.9 B | ||
|
Heska Corporation
HSKA
|
138 | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
104 | - | -20.0 % | $ 1.06 M | ||
|
DermTech
DMTK
|
66.7 | - | -11.32 % | $ 2.94 M | ||
|
Aspira Women's Health
AWH
|
-38.7 | - | -6.19 % | $ 10.5 M | ||
|
Co-Diagnostics
CODX
|
299 | $ 4.4 | 101.83 % | $ 129 M | ||
|
Accelerate Diagnostics
AXDX
|
364 | - | -61.36 % | $ 2.46 M | ||
|
Precipio
PRPO
|
-3.19 | $ 26.6 | - | $ 34.5 M | ||
|
Medpace Holdings
MEDP
|
50.4 | $ 469.11 | 1.82 % | $ 13.5 B | ||
|
Global Cord Blood Corporation
CO
|
184 | - | - | $ 399 M | ||
|
Motus GI Holdings
MOTS
|
3.45 K | - | -34.28 % | $ 263 K | ||
|
Genetic Technologies Limited
GENE
|
11 K | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
142 | - | 0.12 % | $ 80.1 M | ||
|
RadNet
RDNT
|
34.5 | $ 61.87 | 3.34 % | $ 4.65 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
1.21 K | - | - | $ 10.7 B | ||
|
Charles River Laboratories International
CRL
|
65 | $ 163.73 | 2.83 % | $ 8.12 B | ||
|
IQVIA Holdings
IQV
|
73.9 | $ 168.5 | 1.42 % | $ 29 B | ||
|
Organovo Holdings
ONVO
|
-82.8 K | - | -2.3 % | $ 19.4 M | ||
|
OpGen
OPGN
|
4.66 | - | -16.95 % | $ 1.54 M | ||
|
National Research Corporation
NRC
|
29.4 | $ 17.7 | 1.49 % | $ 396 M | ||
|
Biocept
BIOC
|
78.1 | - | -13.05 % | $ 7.29 M | ||
|
Sotera Health Company
SHC
|
33.5 | $ 13.97 | 0.98 % | $ 3.97 B | ||
|
Invitae Corporation
NVTA
|
299 | - | - | $ 21.2 M | ||
|
Soleno Therapeutics
SLNO
|
-398 | $ 33.45 | 6.73 % | $ 1.7 B | ||
|
Interpace Biosciences
IDXG
|
44.9 | $ 1.71 | - | $ 7.5 M | ||
|
Pacific Biosciences of California
PACB
|
185 | $ 1.43 | 2.9 % | $ 429 M | ||
|
QIAGEN N.V.
QGEN
|
122 | - | - | $ 10.6 B | ||
|
Neuronetics
STIM
|
17.3 | $ 1.4 | -3.51 % | $ 92.3 M | ||
|
Personalis
PSNL
|
-11.5 | $ 8.14 | 4.63 % | $ 482 M | ||
|
Chembio Diagnostics
CEMI
|
111 | - | 0.22 % | $ 16.8 M | ||
|
Laboratory Corporation of America Holdings
LH
|
40.3 | $ 267.99 | 0.7 % | $ 22.3 B | ||
|
ENDRA Life Sciences
NDRA
|
-1.24 K | $ 3.22 | -6.94 % | $ 1.73 M | ||
|
NeoGenomics
NEO
|
82.4 | $ 8.06 | 2.54 % | $ 1.03 B | ||
|
Renalytix AI plc
RNLX
|
15.9 | - | 5.66 % | $ 22.7 M | ||
|
CareDx, Inc
CDNA
|
51.5 | $ 18.36 | 2.91 % | $ 978 M | ||
|
Thermo Fisher Scientific
TMO
|
70 | $ 495.14 | 1.04 % | $ 187 B | ||
|
OPKO Health
OPK
|
242 | $ 1.16 | 2.21 % | $ 805 M |